Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Biohacking has moved from niche experiments to a global movement reshaping how we think about human potential. With ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new approach to treating cancer that uses engineered fat cells to deprive tumors ...